<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med. Genet</journal-id><journal-title-group><journal-title>BMC Medical Genetics</journal-title></journal-title-group><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4607013</article-id><article-id pub-id-type="publisher-id">239</article-id><article-id pub-id-type="doi">10.1186/s12881-015-0239-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Mutation in NRAS in familial Noonan syndrome – case report and review of the literature </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ekvall</surname><given-names>Sara</given-names></name><address><email>sara.ekvall@igp.uu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wilbe</surname><given-names>Maria</given-names></name><address><email>maria.wilbe@igp.uu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dahlgren</surname><given-names>Jovanna</given-names></name><address><email>jovanna.dahlgren@gu.se</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Legius</surname><given-names>Eric</given-names></name><address><email>Eric.Legius@uzleuven.be</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>van Haeringen</surname><given-names>Arie</given-names></name><address><email>A.van_Haeringen@lumc.nl</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Westphal</surname><given-names>Otto</given-names></name><address><email>otto.westphal@gu.se</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Annerén</surname><given-names>Göran</given-names></name><address><email>goran.anneren@igp.uu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bondeson</surname><given-names>Marie-Louise</given-names></name><address><phone>+46-18-6115939</phone><email>marielouise.bondeson@igp.uu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Dag Hammarskjölds väg 20, 751 85 Uppsala, Sweden </aff><aff id="Aff2"><label/>Department of Paediatrics, the Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden </aff><aff id="Aff3"><label/>Department of Human Genetics, KU Leuven, Leuven, Belgium </aff><aff id="Aff4"><label/>Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>95</elocation-id><history><date date-type="received"><day>17</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>© Ekvall et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Noonan syndrome (NS), a heterogeneous developmental disorder associated with variable clinical expression including short stature, congenital heart defect, unusual pectus deformity and typical facial features, is caused by activating mutations in genes involved in the RAS-MAPK signaling pathway. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="3" pm="."><plain>Case presentation </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>Here, we present a clinical and molecular characterization of a small family with Noonan syndrome. </plain></SENT>
<SENT sid="5" pm="."><plain>Comprehensive mutation analysis of NF1, PTPN11, SOS1, CBL, BRAF, RAF1, SHOC2, MAP2K2, MAP2K1, SPRED1, NRAS, HRAS and KRAS was performed using targeted next-generation sequencing. </plain></SENT>
<SENT sid="6" pm="."><plain>The result revealed a recurrent mutation in NRAS, c.179G &gt; A (p.G60E), in the index patient. </plain></SENT>
<SENT sid="7" pm="."><plain>This mutation was inherited from the index patient’s father, who also showed signs of NS. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="8" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>We describe clinical features in this family and review the literature for genotype-phenotype correlations for NS patients with mutations in NRAS. </plain></SENT>
<SENT sid="10" pm="."><plain>Neither of affected individuals in this family presented with juvenile myelomonocytic leukemia (JMML), which together with previously published results suggest that the risk for NS individuals with a germline NRAS mutation developing JMML is not different from the proportion seen in other NS cases. </plain></SENT>
<SENT sid="11" pm="."><plain>Interestingly, 50 % of NS individuals with an NRAS mutation (including our family) present with lentigines and/or Café-au-lait spots. </plain></SENT>
<SENT sid="12" pm="."><plain>This demonstrates a predisposition to hyperpigmented lesions in NRAS-positive NS individuals. </plain></SENT>
<SENT sid="13" pm="."><plain>In addition, the affected father in our family presented with a hearing deficit since birth, which together with lentigines are two characteristics of NS with multiple lentigines (previously LEOPARD syndrome), supporting the difficulties in diagnosing individuals with RASopathies correctly. </plain></SENT>
<SENT sid="14" pm="."><plain>The clinical and genetic heterogeneity observed in RASopathies is a challenge for genetic testing. </plain></SENT>
<SENT sid="15" pm="."><plain>However, next-generation sequencing technology, which allows screening of a large number of genes simultaneously, will facilitate an early and accurate diagnosis of patients with RASopathies. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>NRAS</italic></kwd><kwd>Noonan syndrome</kwd><kwd>Mutation</kwd><kwd>RAS-MAPK pathway</kwd><kwd>RASopathies</kwd></kwd-group></SecTag><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="Sec1" sec-type="introduction"><title><text><SENT sid="16" pm="."><plain>Background </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain>Noonan syndrome (NS, OMIM 163950) is a relatively common developmental disorder belonging to the RASopathies, a group of clinically and genetically related syndromes [1, 2]. </plain></SENT>
<SENT sid="18" pm="."><plain>The molecular cause underlying RASopathies is dysregulation of the RAS-MAPK pathway and 15 different genes affecting this pathway have been associated to RASopathies. </plain></SENT>
<SENT sid="19" pm="."><plain>Of these 15 genes, eleven have been found to be involved in NS or NS-like conditions, where mutations in PTPN11 are the cause of ~50 % of the cases. </plain></SENT>
<SENT sid="20" pm="."><plain>The other genes are SOS1 [3, 4], CBL [5–7], BRAF [8], RAF1 [9, 10], SHOC2 [11], MAP2K1 [12], RIT1 [13], NRAS [14], KRAS [15, 16] and RRAS [17]. </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>The main characteristics of NS are short stature, congenital heart defect, unusual pectus deformity and typical facial features, such as hypertelorism, ptosis, down-slanting palpebral fissures, low-set posteriorly rotated ears and a broad forehead. </plain></SENT>
<SENT sid="22" pm="."><plain>However, NS is a clinically variable disorder and additional associated features often present include neonatal failure to thrive, mild mental retardation, various skin manifestations, bleeding abnormalities and multiple skeletal defects [18, 19]. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>NRAS is a four-exon gene, encoding the widely expressed small GTPase NRAS, which act as a membrane-associated molecular switch in the RAS-MAPK pathway [14]. </plain></SENT>
<SENT sid="24" pm="."><plain>To date, only eight unrelated individuals with NS and three NS families have been identified with mutations in NRAS [14, 20–23]. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>Here, we performed a comprehensive molecular analysis of 13 RASopathy-associated genes; NF1, PTPN11, SOS1, CBL, BRAF, RAF1, SHOC2, MAP2K2, MAP2K1, SPRED1, NRAS, HRAS and KRAS, in a family with NS, which revealed a previously reported mutation in NRAS, c.179G &gt; A (p.G60E). </plain></SENT>
<SENT sid="26" pm="."><plain>We describe clinical features in this family and review the literature for genotype-phenotype correlations for NS patients with mutations in NRAS. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CASE"><sec id="Sec2"><title><text><SENT sid="27" pm="."><plain>Case presentation </plain></SENT>
</text></title><p><text><SENT sid="28" pm="."><plain>Clinical investigations and genetic analyses were performed according to the guidelines in the Declaration of Helsinki and approved by the ethical committee of Uppsala University and Gothenburg University, Sweden. </plain></SENT>
<SENT sid="29" pm="."><plain>Informed consent was obtained from all patients and specific permission was given for photographs. </plain></SENT>
</text></p><sec id="Sec3"><title><text><SENT sid="30" pm="."><plain>Case 1 </plain></SENT>
</text></title><p><text><SENT sid="31" pm="."><plain>This is a 28-year-old woman, who got the clinical diagnosis of Noonan syndrome (NS) at the age of 4 years because of growth retardation, cardiomyopathy and facial features. </plain></SENT>
<SENT sid="32" pm="."><plain>She is the only child of non-related parents. </plain></SENT>
<SENT sid="33" pm="."><plain>The father (Case 2) has facial features of NS, but few additional clinical symptoms. </plain></SENT>
<SENT sid="34" pm="."><plain>She was born to a mother with diabetes during pregnancy with a birth weight of 4.7 kg (+3 SDS), a length of 52 cm (+1 SDS) and a head circumference of +2 SDS. </plain></SENT>
<SENT sid="35" pm="."><plain>She also had a large left ventricle, and a systolic murmur, but this disappeared at the age of six years. </plain></SENT>
<SENT sid="36" pm="."><plain>Postnatally, her growth decelerated and she had feeding difficulties. </plain></SENT>
<SENT sid="37" pm="."><plain>At 6.5 years of age, her height was 104 cm (−2 SDS) and her weight 18.5 kg (−2 SDS). </plain></SENT>
<SENT sid="38" pm="."><plain>She had low endogenous growth hormone (GH) secretion defined as “partial GH deficiency”, and started GH therapy within a formal clinical trial (NovoNordisk) from 6.5 years of age. </plain></SENT>
<SENT sid="39" pm="."><plain>She was treated with GH (dose of 66 μg/kg/day) and responded exceptionally well and treatment was discontinued after two years. </plain></SENT>
<SENT sid="40" pm="."><plain>However, at 10 years of age, she had her first pubertal signs and GH-treatment was started again using a standard dose of 33 μg/kg/day. </plain></SENT>
<SENT sid="41" pm="."><plain>At 12.3 years of age, she had menarche. </plain></SENT>
<SENT sid="42" pm="."><plain>The GH-treatment continued until final height (FH) was reached at the age of 14 years. </plain></SENT>
<SENT sid="43" pm="."><plain>Her FH is 164.5 cm (−0.45 SDS) and weight of 60 kg (+0.3 SDS). </plain></SENT>
<SENT sid="44" pm="."><plain>Her psychomotor development is normal, but she has slight problems of attention deficit. </plain></SENT>
<SENT sid="45" pm="."><plain>She attended regular school and works as an assistant nurse. </plain></SENT>
<SENT sid="46" pm="."><plain>At the age of 24 years, she has the following features of NS (Fig. 1a): a large skull (62 cm) with a broad forehead, hypertelorism, down slanted palpebral fissures, bilateral ptosis (especially of her left eye), short and broad neck with a low hairline, and low-set ears with broad helices. </plain></SENT>
<SENT sid="47" pm="."><plain>Her hair is normal. </plain></SENT>
<SENT sid="48" pm="."><plain>She has two large Café-au-lait spots on her back and &gt;50 freckles (lentigines) all over her body, especially on her back (Fig. 1b) and arms (Fig. 1c).Fig. 1Photograph of the index patient affected by NS with a mutation in NRAS, p.G60E. a Facial features. b The back with multiple lentigines. c The left arm with multiple lentigines </plain></SENT>
</text></p></sec><sec id="Sec4"><title><text><SENT sid="49" pm="."><plain>Case 2 </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>This is the 62-year-old father of Case 1. </plain></SENT>
<SENT sid="51" pm="."><plain>He was clinically diagnosed after Case 1 was diagnosed. </plain></SENT>
<SENT sid="52" pm="."><plain>He has facial features of NS, but few additional clinical symptoms. </plain></SENT>
<SENT sid="53" pm="."><plain>Sensorineural hearing impairment was present at birth. </plain></SENT>
<SENT sid="54" pm="."><plain>His growth pattern was normal, but he had a delayed puberty. </plain></SENT>
<SENT sid="55" pm="."><plain>His FH is 175.0 cm (−0.4 SDS) and weight 75 kg (±0 SDS). </plain></SENT>
<SENT sid="56" pm="."><plain>The intellectual development was normal. </plain></SENT>
<SENT sid="57" pm="."><plain>He followed normal school and university education and worked as a librarian until the age of 55 years, when he had to retire because of tinnitus. </plain></SENT>
<SENT sid="58" pm="."><plain>At the age of 62 years, he has the following features of NS (Fig. 2a–c): slight macrocephaly (61 cm, +2 SDS), bilateral ptosis, hypertelorism and down-slanting palpebral fissures. </plain></SENT>
<SENT sid="59" pm="."><plain>He also has curly hair and lentigines on his back. </plain></SENT>
<SENT sid="60" pm="."><plain>He had a cardiac murmur in childhood that disappeared spontaneously.Fig. 2Photograph of the affected father with the same NRAS mutation, p.G60E. a Frontal facial features. b Additional facial features. c The back with multiple lentigines </plain></SENT>
</text></p></sec><sec id="Sec5"><title><text><SENT sid="61" pm="."><plain>Methods </plain></SENT>
</text></title><p><text><SENT sid="62" pm="."><plain>Genomic DNA from the index patient and her father was extracted from peripheral blood leukocytes according to standard procedures. </plain></SENT>
</text></p><sec id="Sec6"><title><text><SENT sid="63" pm="."><plain>Mutation analysis </plain></SENT>
</text></title><p><text><SENT sid="64" pm="."><plain>The index patient was analyzed for variants in all coding exons and exon-intron boundaries of NF1 (NM_000267.3), PTPN11 (NM_002834), SOS1 (NM_005633), CBL (NM_005188), BRAF (NM_004333), RAF1 (NM_002880), SHOC2 (NM_007373), MAP2K2 (NM_030662), MAP2K1 (NM_002755), SPRED1 (NM_152594), NRAS (NM_002524), HRAS (NM_005343) and KRAS (NM_004985) using Agilent HaloPlex Target Enrichment (Agilent Technologies, Inc., Santa Clara, CA, USA), followed by next-generation sequencing on MiSeq, Illumina (Illumina, Inc., San Diego, CA, USA). </plain></SENT>
<SENT sid="65" pm="."><plain>Data analysis was performed by NextGENe software v2.3.1 (SoftGenetics, LLC., State College, PA, USA) and BENCHlab NGS (Cartagenia, Inc., Cambridge, MA, USA) [Ekvall et al. Manuscript in preparation]. </plain></SENT>
</text></p><p><text><SENT sid="67" pm="."><plain>Variants observed in NRAS exon 2 were verified by bi-directional Sanger sequencing in the index patient and her father. </plain></SENT>
<SENT sid="68" pm="."><plain>Primer sequences and PCR conditions are available upon request. </plain></SENT>
</text></p></sec></sec><sec id="Sec7"><title><text><SENT sid="69" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="70" pm="."><plain>DNA sequencing analysis of the index patient (Fig. 1) was performed on 13 RASopathy-associated genes using HaloPlex target enrichment (Agilent) and next-generation sequencing on MiSeq (Illumina). </plain></SENT>
<SENT sid="71" pm="."><plain>Coverage and read depth of the RASopathy genes in the index patient is shown in Table 1. </plain></SENT>
<SENT sid="72" pm="."><plain>Targeted bases in region of interest (ROI) with &gt;30X read depth was 100 % for all genes, except NF1 (99.8 %) and SOS1 (99.9 %). </plain></SENT>
<SENT sid="73" pm="."><plain>No complementary Sanger sequencing was performed. </plain></SENT>
<SENT sid="74" pm="."><plain>A heterozygous missense mutation, c.179G &gt; A; p.G60E, in exon 2 of NRAS was identified and verified using Sanger sequencing. </plain></SENT>
<SENT sid="75" pm="."><plain>This mutation was inherited from the father (Fig. 2), who also shows signs of NS. </plain></SENT>
<SENT sid="76" pm="."><plain>No additional variants of significance were identified in the index patient.Table 1Average read depth and coverage of RASopathy-associated genes in this studyGeneReference sequenceROIa basesExonsAverage read depthCoverage &gt;30X (%) BRAF NM_00433330211812 637100. 0 CBL NM_00518833611612 016100.0 HRAS NM_005343812614 291100.0 KRAS NM_004985768510 811100.0 MAP2K1 NM_00275516221112 525100.0 MAP2K2 NM_03066216431111 127100.0 NF1 NM_000267107375812 72899.8 NRAS NM_002524861716 378100.0 PTPN11 NM_00283465211616 262100.0 RAF1 NM_00288025871615 985100.0 SHOC2 NM_0073732069817 812100.0 SOS1 NM_00563349222313 43999.9 SPRED1 NM_1525941615710 509100.0 a ROI Region of interest </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec id="Sec8" sec-type="conclusions"><title><text><SENT sid="77" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="78" pm="."><plain>To date, only eight unrelated patients with NS and three NS families have been reported positive for NRAS mutations (p.G13D, p.I24N, p.P24L, p.T50I and p.G60E) [14, 20–23]. </plain></SENT>
<SENT sid="79" pm="."><plain>In this study, we describe an additional family with NS, where the index patient and her father have c.179G &gt; A (p.G60E). </plain></SENT>
<SENT sid="80" pm="."><plain>This mutation has been identified in both sporadic and familial NS patients of European origin [14, 23] and is the most common germline mutation in NRAS. </plain></SENT>
</text></p><p><text><SENT sid="81" pm="."><plain>NS patients with NRAS mutations often show a relatively mild phenotype of typical Noonan facial features. </plain></SENT>
<SENT sid="82" pm="."><plain>A comparison of previously reported NRAS-associated NS cases shows that all of the patients present with typical Noonan facial features (14/14) and 11/13 have macrocephaly or relative macrocephaly, but only half of them display congenital heart defects (7/14). </plain></SENT>
<SENT sid="83" pm="."><plain>All previously reported patients also show short stature. </plain></SENT>
<SENT sid="84" pm="."><plain>However, in the family reported here the father’s height was normal, while the daughter had short stature successfully treated with GH. </plain></SENT>
<SENT sid="85" pm="."><plain>The majority has pterygium or webbing of the neck (10/12). </plain></SENT>
<SENT sid="86" pm="."><plain>Thorax deformity (pectus excavatum) occurs in 5/14 patients, while easy bruising is less common (3/14). </plain></SENT>
<SENT sid="87" pm="."><plain>Half of the males show cryptorchidism (6/10) and ophthalmological problems appear in 4/14 patients. </plain></SENT>
<SENT sid="88" pm="."><plain>Motor delay is common (9/14 patients) and as previously reported, intellectual development is often mildly delayed (6 patients normal and 8 mildly delayed). </plain></SENT>
<SENT sid="89" pm="."><plain>Keratosis pilaris/hyperkeratosis is less common (4/12 patients) and hair abnormalities occur in about half of the patients. </plain></SENT>
<SENT sid="90" pm="."><plain>Of note, lentigines are observed in six patients, but leukemia/cancer are rarely seen (1 patient with JMML) (Table 2) [14, 20–23]. </plain></SENT>
<SENT sid="91" pm="."><plain>Somatic mutations affecting genes in the RAS-MAPK pathway are associated with cancer, and NS and related disorders are known to cause a predisposition to cancer [24]. </plain></SENT>
<SENT sid="92" pm="."><plain>Somatic mutations in NRAS are involved in the development of hematological malignancies and in a variety of solid tumors (COSMIC database; <ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/">http://cancer.sanger.ac.uk/</ext-link>). </plain></SENT>
<SENT sid="93" pm="."><plain>However, germline NRAS mutations differ from most common somatic NRAS mutations associated with malignancies and are less activating in dysregulating intracellular signaling [18].Table 2Clinical features of patients with Noonan syndrome caused by NRAS mutations#1234567899 M10111212 FPatientDe Filippi et al. [20]Runtuwene et al. [21]Denayer et al. [22]Denayer et al. [22]Denayer et al. [22]Cirstea et al. [14]Cirstea et al. [14]Cirstea et al. [14]Cirstea et al. [14]Cirstea et al. [14]Kraoua et al. [23]Kraoua et al. [23]Present studyPresent study NRAS mutationp.G13Dp.I24Np.I24Np.P24Lp.T50Ip.T50Ip.T50Ip.G60Ep.G60Ep.G60Ep.G60Ep.G60Ep.G60Ep.G60EOrigin of mutation de novo  de novo  de novo InheritedND de novo  de novo  de novo InheritedNDND (probably inherited) de novo InheritedND (probably inherited)Paternal age at conceptionND26 yearsNDNDND50 years34 years31 years47 years44 years45 years47 years34 yearsNDAge at last examination3 years30 years13 years19 years2.5 years14 years7 years3.3 years20 years50 years24 years3 months28 years62 yearsGenderMaleMaleMaleMaleMaleMaleMaleFemaleMaleFemaleMaleFemaleFemaleMalePrenatal findingsNDPolyhydramniosNDNDNDNuchal edema, PolyhydramniosPolyhydramniosSingle umbilical artery--PolyhydramniosPyelectasis--Congenital heart defect---NDCoarctation aortae, Patent foramen ovaleHCMPSMild HCM, Mitral valve dysplasia, PS---PSASD, HCMCardiac murmurRythm disturbanceND-NDND-SVES--------Typical facial features++++++++++++++Stature5–10th centileMild short&lt;3rd centile10th–25th centile10th–25th centile10th centilea &lt;3rd centile&lt;3rd centile&gt;10th centile10th centile3rd centile3rd–10th centile50th centilea 50th centileMacrocephalyRelative&gt;90th centile&gt;97th centileND25th–50th centile+Relative-++RelativeRelative+RelativePterygium colli/Webbed neck-+NDND++-+++++++Thorax deformity-Pectus excavatumPectus excavatumNDPectus excavatum+-Pectus excavatum++Mildly depressed thoraxPectus excavatum--Easy bruising--ND+ND-----+ND+-Cryptorchidism-++ND+++NA+NA-NANA-Ophthalmological problemsND-Strabismus, Bilateral keratoconus of the corneaNDNDMyopia---Myopia--Astigmatis, Myopia, Strabismus-Motor delay/Muscular hypotonia-Motor delayMildNDNDMild++++Mild+--Mental developmentNormalMild learning difficultiesNormalLearning difficultiesNormalNormalBorderlineSpeech delayNormal-borderlineNormalSpeech delay, dyscalculyNAADHD, normal IQNormalKeratosis pilaris/HyperkeratosisND-NDNDNDSevere-+++ND---Hair abnormalities--NDNDNDCurly hairCurly hairSparse thin hairCurly hair--Curly hair-Curly hairLentigines/Café-au-lait spots+Some lentigines--------++++Leukemia/CancerJMML-------------Other-Oligospermia-Inadequate visio-spatial orientation skills, Inguinal hernia, Delayed pubertal development-Pes equinovarus-Palpebral ptosisIchtyosiform eczema, Acanthosis nigricans, ScoliosisMother of patient 9Palpebral ptosis, Inguinal hernia, ScoliosisPalpebral ptosis, Unilateral pyelectasis-Sensory-neural hearing deficit, Father of patient 12 ASD atrial septal defect, HCM hypertrophic cardiomyopathy, JMML juvenile myelomonocytic leukemia, NA not applicable, ND not determined, PS pulmonic stenosis, SVES supraventricular extrasystole aReceived growth hormone treatment from the age of 8 years, when partial growth hormone deficiency had been noted </plain></SENT>
</text></p><p><text><SENT sid="94" pm="."><plain>In summary, we report an NS family with a p.G60E in NRAS. </plain></SENT>
<SENT sid="95" pm="."><plain>Neither of affected individuals presented with JMML. </plain></SENT>
<SENT sid="96" pm="."><plain>Thus, the proportion of JMML observed in NRAS patients (1/12) is comparable with the observed proportion of JMML in NS in general [25]. </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>Interestingly, half of the patients (including affected individuals in our family) presented with lentigines and/or Café-au-lait spots, which is high compared to the prevalence of 3 % for lentigines and 10 % for Café-au-lait spots in the general NS population [26]. </plain></SENT>
<SENT sid="98" pm="."><plain>Multiple nevi, lentigines and/or Café-au-lait spots are also detectable in one-third of NS individuals with a RAF1 mutation and previous studies have demonstrated a higher prevalence of these features in BRAF-positive NS individuals as well. </plain></SENT>
<SENT sid="99" pm="."><plain>This suggests that NS individuals with a mutation in NRAS, RAF1 or BRAF have a predisposition to hyperpigmented cutaneous lesions [8, 27]. </plain></SENT>
<SENT sid="100" pm="."><plain>Of note, the father in our family presented with congenital sensorineural hearing impairment, which together with lentigines are two common features in Noonan syndrome with multiple lentigines (NS-ML, previously LEOPARD syndrome). </plain></SENT>
<SENT sid="101" pm="."><plain>This demonstrates the wide spectrum of phenotypes within each syndrome as well as the clinical overlap between RASopathies, which makes diagnosis of NS and related disorders challenging. </plain></SENT>
</text></p><p><text><SENT sid="102" pm="."><plain>However, by using the advent of next-generation sequencing technology, which allow for screening of a large number of genes simultaneously, an early and accurate genetic diagnosis of patients with RASopathies will be facilitated. </plain></SENT>
</text></p></sec></SecTag><sec id="Sec9"><title><text><SENT sid="103" pm="."><plain>Consent </plain></SENT>
</text></title><p><text><SENT sid="104" pm="."><plain>We have obtained written informed consent from the patients for publication of this case report and accompanying images. </plain></SENT>
<SENT sid="105" pm="."><plain>A copy of the written consent is available from the Editor of this journal. </plain></SENT>
</text></p></sec></body><back><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>NS</term><def><p>Noonan syndrome</p></def></def-item><def-item><term>MAPK</term><def><p>Mitogen-activated protein kinase</p></def></def-item><def-item><term>JMML</term><def><p>Juvenile myelomonocytic leukemia</p></def></def-item><def-item><term>GH</term><def><p>Growth hormone</p></def></def-item><def-item><term>ROI</term><def><p>Region of interest</p></def></def-item><def-item><term>COSMIC</term><def><p>Catalogue of somatic mutations in cancer</p></def></def-item><def-item><term>ASD</term><def><p>Atrial septal defect</p></def></def-item><def-item><term>HCM</term><def><p>Hypertrophic cardiomyopathy</p></def></def-item><def-item><term>NA</term><def><p>Not applicable</p></def></def-item><def-item><term>ND</term><def><p>Not determined</p></def></def-item><def-item><term>PS</term><def><p>Pulmonic stenosis</p></def></def-item><def-item><term>SVES</term><def><p>Supraventricular extrasystole</p></def></def-item></def-list></glossary></SecTag><fn-group><fn><p><text><SENT sid="106" pm="."><plain>Competing interests </plain></SENT>
</text></p><p><text><SENT sid="107" pm="."><plain>The authors declare that there are no conflicts of interest in connection with this article. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="108" pm="."><plain>Authors’ contributions </plain></SENT>
</text></p><p><text><SENT sid="109" pm="."><plain>MLB, GA and SE conceived the study and participated in its design. </plain></SENT>
<SENT sid="110" pm="."><plain>GA, JD, OW, EL and AVH performed clinical examination of the patients. </plain></SENT>
<SENT sid="111" pm="."><plain>SE, MLB and MW carried out the molecular genetic studies and interpreted the data. </plain></SENT>
<SENT sid="112" pm="."><plain>SE drafted the manuscript with input from the other co-authors. </plain></SENT>
<SENT sid="113" pm="."><plain>All authors read and approved the final manuscript. </plain></SENT>
</text></p></fn></fn-group><SecTag type="ACK_FUND"><ack><title>Acknowledgements</title><p><text4fund><text><SENT sid="114" pm="."><plain>This study was supported by grants from the Swedish Research Council, the Borgström foundation, the Sävstaholm foundation and foundations at the Medical Faculty of Uppsala University, Sweden. </plain></SENT>
<SENT sid="115" pm="."><plain>The authors wish to thank the family for participating in this study. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="116" pm="."><plain>1.RobertsAEAllansonJETartagliaMGelbBDNoonan syndromeLancet2013381986333334210.1016/S0140-6736(12)61023-X<?supplied-pmid 23312968?>23312968 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="117" pm="."><plain>2.TartagliaMGelbBDDisorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanismsAnn N Y Acad Sci201012149912110.1111/j.1749-6632.2010.05790.x<?supplied-pmid 20958325?>20958325 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="118" pm="."><plain>3.RobertsAEArakiTSwansonKDMontgomeryKTSchiripoTAJoshiVALiLYassinYTamburinoAMNeelBGGermline gain-of-function mutations in SOS1 cause Noonan syndromeNat Genet2007391707410.1038/ng1926<?supplied-pmid 17143285?>17143285 </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="119" pm="."><plain>4.TartagliaMPennacchioLAZhaoCYadavKKFodaleVSarkozyAPanditBOishiKMartinelliSSchackwitzWGain-of-function SOS1 mutations cause a distinctive form of Noonan syndromeNat Genet2007391757910.1038/ng1939<?supplied-pmid 17143282?>17143282 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="120" pm="."><plain>5.MartinelliSChecquoloSConsoliFStellacciERossiCSilvanoMFranciosaGFlexECossuCDe LucaALoss of CBL E3-ligase activity in B-lineage childhood acute lymphoblastic leukaemiaBr J Haematol2012159111511910.1111/j.1365-2141.2012.09245.x<?supplied-pmid 22834886?>22834886 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="121" pm="."><plain>6.NiemeyerCMKangMWShinDHFurlanIErlacherMBuninNJBundaSFinklesteinJZSakamotoKMGorrTAGermline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemiaNat Genet201042979480010.1038/ng.641<?supplied-pmid 20694012?>20694012 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="122" pm="."><plain>7.PerezBMechinaudFGalambrunCBen RomdhaneNIsidorBPhilipNDerain-CourtJCassinatBLachenaudJKaltenbachSGermline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemiaJ Med Genet2010471068669110.1136/jmg.2010.076836<?supplied-pmid 20543203?>20543203 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="123" pm="."><plain>8.SarkozyACartaCMorettiSZampinoGDigilioMCPantaleoniFSciolettiAPEspositoGCordedduVLepriFGermline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrumHum Mutat200930469570210.1002/humu.20955<?supplied-pmid 19206169?>19206169 </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="124" pm="."><plain>9.PanditBSarkozyAPennacchioLACartaCOishiKMartinelliSPognaEASchackwitzWUstaszewskaALandstromAGain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathyNat Genet20073981007101210.1038/ng2073<?supplied-pmid 17603483?>17603483 </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="125" pm="."><plain>10.RazzaqueMANishizawaTKomoikeYYagiHFurutaniMAmoRKamisagoMMommaKKatayamaHNakagawaMGermline gain-of-function mutations in RAF1 cause Noonan syndromeNat Genet20073981013101710.1038/ng2078<?supplied-pmid 17603482?>17603482 </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="126" pm="."><plain>11.CordedduVDi SchiaviEPennacchioLAMa'ayanASarkozyAFodaleVCecchettiSCardinaleAMartinJSchackwitzWMutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hairNat Genet20094191022102610.1038/ng.425<?supplied-pmid 19684605?>19684605 </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="127" pm="."><plain>12.NavaCHannaNMichotCPereiraSPouvreauNNiihoriTAokiYMatsubaraYArveilerBLacombeDCardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndromeJ Med Genet2007441276377110.1136/jmg.2007.050450<?supplied-pmid 17704260?>17704260 </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="128" pm="."><plain>13.AokiYNiihoriTBanjoTOkamotoNMizunoSKurosawaKOgataTTakadaFYanoMAndoTGain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndromeAm J Hum Genet201393117318010.1016/j.ajhg.2013.05.021<?supplied-pmid 23791108?>23791108 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="129" pm="."><plain>14.CirsteaICKutscheKDvorskyRGremerLCartaCHornDRobertsAELepriFMerbitz-ZahradnikTKonigRA restricted spectrum of NRAS mutations causes Noonan syndromeNat Genet2010421272910.1038/ng.497<?supplied-pmid 19966803?>19966803 </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="130" pm="."><plain>15.CartaCPantaleoniFBocchinfusoGStellaLVastaISarkozyADigilioCPalleschiAPizzutiAGrammaticoPGermline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotypeAm J Hum Genet200679112913510.1086/504394<?supplied-pmid 16773572?>16773572 </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="131" pm="."><plain>16.SchubbertSZenkerMRoweSLBollSKleinCBollagGvan der BurgtIMusanteLKalscheuerVWehnerLEGermline KRAS mutations cause Noonan syndromeNat Genet200638333133610.1038/ng1748<?supplied-pmid 16474405?>16474405 </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="132" pm="."><plain>17.FlexEJaiswalMPantaleoniFMartinelliSStrulluMFansaEKCayeADe LucaALepriFDvorskyRActivating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesisHum Mol Genet201423164315432710.1093/hmg/ddu148<?supplied-pmid 24705357?>24705357 </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="133" pm="."><plain>18.AllansonJENoonan syndromeJ Med Genet198724191310.1136/jmg.24.1.9<?supplied-pmid 3543368?>3543368 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="134" pm="."><plain>19.van der BurgtINoonan syndromeOrphanet J Rare Dis20072410.1186/1750-1172-2-4<?supplied-pmid 17222357?>17222357 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="135" pm="."><plain>20.De FilippiPZeccaMLisiniDRostiVCagioniCCarlo-StellaCRadiOVeggiottiPMastronuzziAAcquavivaAGerm-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemiaBr J Haematol2009147570670910.1111/j.1365-2141.2009.07894.x<?supplied-pmid 19775298?>19775298 </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="136" pm="."><plain>21.RuntuweneVvan EekelenMOvervoordeJRehmannHYntemaHGNillesenWMvan HaeringenAvan der BurgtIBurgeringBden HertogJNoonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defectsDis Model Mech20114339339910.1242/dmm.007112<?supplied-pmid 21263000?>21263000 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="137" pm="."><plain>22.DenayerEPeetersHSevenantsLDerbentMFrynsJPLegiusENRAS Mutations in Noonan SyndromeMol Syndromol2012313438<?supplied-pmid 22855653?>22855653 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="138" pm="."><plain>23.KraouaLJournelHBonnetPAmielJPouvreauNBaumannCVerloesACaveHConstitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemiaAm J Med Genet A2012158A102407241110.1002/ajmg.a.35513<?supplied-pmid 22887781?>22887781 </plain></SENT>
</text></ref><ref id="CR24"><text><SENT sid="139" pm="."><plain>24.KratzCPFrankeLPetersHKohlschmidtNKazmierczakBFinckhUBierAEichhornBBlankCKrausCCancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromesBr J Cancer201511281392139710.1038/bjc.2015.75<?supplied-pmid 25742478?>25742478 </plain></SENT>
</text></ref><ref id="CR25"><text><SENT sid="140" pm="."><plain>25.StrulluMCayeALachenaudJCassinatBGazalSFenneteauOPouvreauNPereiraSBaumannCContetAJuvenile myelomonocytic leukaemia and Noonan syndromeJ Med Genet2014511068969710.1136/jmedgenet-2014-102611<?supplied-pmid 25097206?>25097206 </plain></SENT>
</text></ref><ref id="CR26"><text><SENT sid="141" pm="."><plain>26.Noonan Syndrome.[<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK1124/">http://www.ncbi.nlm.nih.gov/books/NBK1124/</ext-link>] </plain></SENT>
</text></ref><ref id="CR27"><text><SENT sid="142" pm="."><plain>27.TartagliaMZampinoGGelbBDNoonan syndrome: clinical aspects and molecular pathogenesisMol Syndromol20101122610.1159/000276766<?supplied-pmid 20648242?>20648242 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
